Literature DB >> 8798523

The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.

K Senechal1, J Halpern, C L Sawyers.   

Abstract

The CRKL adaptor protein was recently identified as a substrate for the BCR-ABL tyrosine kinase in patients with chronic myelogenous leukemia, but its function is unknown. Here we report that CRKL is phosphorylated when overexpressed, activates RAS and JUN kinase signaling pathways, and transforms fibroblasts in a RAS-dependent fashion. We examined the potential role of CRKL in BCR-ABL function by deleting the CRKL binding site in BCR-ABL. This mutant BCR-ABL protein shows a 50% reduction in fibroblast transforming activity. The GRB2 adaptor protein has previously been implicated in this pathway, presumably linking BCR-ABL to RAS. To address the relative roles of CRKL and GRB2 in this system, we compared BCR-ABL mutants with defects in binding to one or both adaptors. Whereas each single mutant showed a 2-3-fold loss in transforming activity, the double mutant showed a 15-fold reduction, suggesting that GRB2 and CRKL both contribute to BCR-ABL transformation. These results demonstrate the oncogenic potential of CRKL and provide functional evidence that CRKL plays a role in fibroblast transformation by BCR-ABL in conjunction with other adaptor proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798523     DOI: 10.1074/jbc.271.38.23255

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Interaction of hematopoietic progenitor kinase 1 with adapter proteins Crk and CrkL leads to synergistic activation of c-Jun N-terminal kinase.

Authors:  P Ling; Z Yao; C F Meyer; X S Wang; W Oehrl; S M Feller; T H Tan
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  CRKL protein overexpression enhances cell proliferation and invasion in pancreatic cancer.

Authors:  Lin Fu; Qianze Dong; Chengyao Xie; Yan Wang; Qingchang Li
Journal:  Tumour Biol       Date:  2014-10-16

3.  MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.

Authors:  Tri K Nguyen; Mohamed Rahmani; Hisashi Harada; Paul Dent; Steven Grant
Journal:  Blood       Date:  2007-01-11       Impact factor: 22.113

4.  Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes.

Authors:  Yi-Ran Cai; Yu-Jie Dong; Hong-Bo Wu; Da-Ping Yu; Li-Juan Zhou; Dan Su; Li Zhang; Xue-Jing Chen
Journal:  Oncol Lett       Date:  2016-09-02       Impact factor: 2.967

5.  Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.

Authors:  K Senechal; C Heaney; B Druker; C L Sawyers
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

6.  Murine model indicates 22q11.2 signaling adaptor CRKL is a dosage-sensitive regulator of genitourinary development.

Authors:  Meade Haller; Qianxing Mo; Akira Imamoto; Dolores J Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

7.  CrkII transgene induces atypical mammary gland development and tumorigenesis.

Authors:  Kelly E Fathers; Sonia Rodrigues; Dongmei Zuo; Indrani Vasudeva Murthy; Michael Hallett; Robert Cardiff; Morag Park
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

8.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

9.  Models of crk adaptor proteins in cancer.

Authors:  Emily S Bell; Morag Park
Journal:  Genes Cancer       Date:  2012-05

10.  A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.

Authors:  Kara J Johnson; Ian J Griswold; Thomas O'Hare; Amie S Corbin; Marc Loriaux; Michael W Deininger; Brian J Druker
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.